Nectin4-targeted fluorescence imaging probe improves bladder cancer detection and surgical precision
By
Jie Tian6 Send email to [email protected]
Summary
This article presents the development of NECTIN4-ICG, a Nectin4-targeted fluorescence imaging probe for bladder cancer diagnosis and surgery. By conjugating indocyanine green (ICG) to enfortumab vedotin, the researchers created a probe that specifically targets Nectin4, a membrane protein highly expressed in bladder cancer. In mouse models, NECTIN4-ICG enabled targeted detection and doubled the complete tumor resection rate. An ex vivo study of 18 fresh human bladders (82 specimens) showed that NECTIN4-ICG-guided biopsy achieved 96.3% diagnostic accuracy, significantly outperforming conventional white light cystoscopy for real-time visualization and surgical precision during transurethral resection.
Source
bskyNectin4-targeted fluorescence imaging probe improves bladder cancer detection and surgical precisioncell.comKey quotes
· 3 pulledNECTIN4-ICG enables targeted detection and doubles the complete tumor resection rate.
NECTIN4-ICG-guided biopsy achieves 96.3% diagnostic accuracy.
Nectin4, a membrane protein highly expressed in BC, is an attractive molecular imaging target.
You might also wanna read
Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives
This article discusses the emerging role of antibody-drug conjugates (ADCs) in the perioperative treatment of muscle-invasive bladder cancer
mdsc.pe·4d ago
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from
Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors
This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago
MIT Develops Noninvasive Glucose Monitoring Device Using Raman Spectroscopy
MIT researchers have developed a noninvasive device using Raman spectroscopy to measure blood glucose levels without finger pricks. The shoe
news.mit.edu·6mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.